Table 3.

Polymorphism frequency in Cdx2, FokI, BsmI, ApaI, TaqI region of VDR gene in patients and controls and association with osteosarcoma risk.

	VDR aleli	Hasta	Kontrol	OR	%95 CI	p
FoxI	Wild	36 (%62.0)	37 (%49.3)	1.68	0.83–3.37	0.14
	Heterozygous polimorphic	18 (%31)	32 (%42.7)	0.60	0.29–1.24	0.17
	Homozygous polimorphic	4 (%6.9)	6 (%8.0)	0.85	0.22–3.17	0.81
Bsm1	Wild	16 (%27.6)	28 (%37.3)	0.63	0.30–1.34	0.23
	Heterozygous polimorphic	35 (%60.3)	38 (%50.7)	1.48	0.74–2.96	0.26
	Homozygous polimorphic	7 (%12.1)	9 (%1.02)	1.07	0.35–2.88	0.99
Apa1	Wild	19 (%32.8)	26 (%34.7)	0.97	0.47–2.01	0.94
	Heterozygous polimorphic	31 (%53.4)	33 (%44.0)	1.46	0.73–2.90	0.28
	Homozygous polimorphic	8 (%13.8)	16 (%21.3)	0.59	2.23–1.49	0.26
Taq1	Wild	22 (%37.9)	31 (%41.3)	0.86	0.43–1.75	0.69
	Heterozygous polimorphic	33 (%56.9)	37 (%49.3)	1.35	0.38–2.70	0.38
	Homozygous polimorphic	3 (%5.2)	7 (%9.3)	0.53	0.13–2.14	0.36
Cdx2	Wild	36 (%62.1)	48 (%64.0)	0.92	0.45–1.87	0.82
	Heterozygous polimorphic	20 (%34.5)	24 (%32.0)	1.12	0.54–2.31	0.76
	Homozygous polimorphic	2 (%3.4)	3 (%4.0)	0.85	0.13–2.31	0.87